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Abstract: Bivalirudin is a member of the direct thrombin inhibitor group of anticoagulants.
It has been evaluated as an alternative to unfractionated and low-molecular-weight heparins
in the settings of percutaneous coronary intervention (PCI) and acute coronary syndrome
(ACS). Results of clinical trials to date suggest bivalirudin is a viable alternative to the use of
a heparin combined with a glycoprotein (GP) IIb/IIIa inhibitor in these settings. Thrombin
has a central role in coagulation and platelet activation in ACS and during PCI. Its direct
inhibition is an attractive target for therapy in these settings. Bivalirudin is a 20 amino acid
polypeptide hirudin analog. It displays bivalent and reversible binding to the thrombin
molecule, inhibiting its action. Direct inhibition of thrombin with bivalirudin has theoretical
pharmacokinetic and pharmacodynamic advantages over the indirect anticoagulants. A
reduction in rates of bleeding without loss of anti-thrombotic efficacy has been a consistent
finding across multiple clinical trials. There may be economic benefits to the use of bivalirudin
if it permits a lower rate of use of the GP IIb/IIIa inhibitors. This article reviews the
pharmacology of bivalirudin and clinical trial evidence to date. There are now data from
multiple clinical trials and meta-analyses in the setting of ACS and PCI. Early results from
the acute catheterization and urgent intervention strategy (ACUITY) trial are discussed.
Keywords: bivalirudin, direct thrombin inhibitor, acute coronary syndrome, percutaneous
coronary intervention
Introduction
Anticoagulation is required during percutaneous coronary intervention (PCI) to
prevent peri-procedural thrombotic complications. Unfractionated heparin (UFH)
and more recently the low molecular weight heparins (LMWHs) are the most common
form of anticoagulation used during PCI (Smith et al 2005). Recently, the direct
thrombin inhibitor (DTI) class of compounds has been evaluated as an alternative
form of anticoagulation during PCI (Bittl et al 1995; Lincoff et al 2002, 2004a).
Bivalirudin is a member of the direct thrombin inhibitor class of compounds. The
pharmacology and early trial evidence have pointed to unique benefits of this
molecule. These are predictable pharmacokinetics, a reduction in bleeding
complications and avoidance of heparin induced thrombocytopenia (HIT). In the
clinical trials reported to date, these advantages have occurred without a loss of
efficacy in thrombotic end-points.
Thrombin in cardiovascular disease
Coagulation has previously been considered as a cascade model with an intrinsic
and extrinsic component meeting in a final common pathway (MacFarlane et al 1964).
The last decade has provided evidence of a more complex system than the linear
model first proposed. Following vessel injury, there are multiple interactions between
coagulation proteins, cellular components, and the vessel wall (Becker et al 2005).
The interaction between tissue factor and factor VII is an initiating event in the
coagulation cascade, promoting the generation of thrombin from prothrombin.
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Thrombin is responsible for fibrin deposition, and the further
activation of platelets, endothelial cells, and leukocytes.
Thrombin activates platelets by binding directly to cell
surface receptors. Protease activated receptor (PAR)-1 and
to a lesser extent PAR-4 is particularly important for platelet
activation (Andersen et al 1999; De Candia et al 2001;
Soslau et al 2001). This mechanism of platelet activation is
independent of prostaglandin and adenosine diphosphate.
It is therefore not inhibited by aspirin or the thiopyridines
such as clopidogrel. Activation of the coagulation pathway
is regulated by natural anticoagulants. These are tissue factor
pathway inhibitor, protein C and S, and antithrombin.
The critical role of thrombin in response to local tissue
injury makes its inhibition an attractive target to prevent
thrombotic complications during PCI. The action of
thrombin can be inhibited by binding to three domains, the
active (or catalytic) site, and two exosites (Tulinsky et al
1996) (Figure 1). Exosite 1 is located next to the active site
and binds fibrin. Exosite 2 acts as the heparin-binding
domain.
Pharmacology of bivalirudin
The DTIs are related in structure to the naturally occurring
hirudin molecule. Members of the DTI class of molecules
can be classified as univalent or bivalent depending on their
interaction with the thrombin molecule. Bivalent DTIs block
thrombin at both the active site and exosite-1, whereas the
univalent molecules bind only to the active site (Maraganore
et al 1990). By reducing the thrombin-mediated activity of
platelets, DTIs also exert an anti-platelet effect (Xiao and
Theroux 1998; Sarich et al 2003). The DTIs also have the
advantage of inhibiting both circulating and clot bound
thrombin (Weitz et al 1990, 1998; Bates et al 2000). While
circulating thrombin is inactivated by indirect
anticoagulants, the clot bound thrombin is not.
Bivalirudin is a synthetic 20 amino acid polypeptide
hirudin analog. It displays bivalent and reversible binding
to the thrombin molecule (Parry et al 1994). Bivalirudin
displays linear pharmacokinetics. Its low oral bioavailability
means it is given as an intravenous infusion. There is a small
volume of distribution and a short half-life of 25 minutes
(White et al 2005). Bivalirudin is predominantly cleared by
intracellular proteolysis. The remaining unchanged drug is
cleared renally. It has been estimated the renal component
of clearance is around 20% (Reed et al 2002).
The pharmacokinetics and pharmacodynamics of
bivalirudin have been evaluated in the setting of renal
impairment (Robson et al 2002). In mild renal impairment,
the clearance of bivalirudin is not reduced enough to be
clinically significant. In moderate renal impairment, the
clearance of bivalirudin is reduced by 20%. The clinical
recommendation is for a 20% reduction in the infusion dose
of bivalirudin in moderate renal impairment.
Activated clotting time (ACT) is used to guide UFH dose
in PCI. There is a modest relationship between ACT and
bleeding complications with UFH (Brener et al 2004). The
relationship between ACT and ischemic complications from
PCI with UFH is thought to be reduced by modern anti-
platelet and stent technology. The relationship between ACT
and bleeding or thrombotic complication does not exist with
bivalirudin (Cheneau et al 2004). It appears that monitoring
of anticoagulant effect is not required with bivalirudin.
Bivalirudin has been shown to reduce the time spent in the
recovery area following PCI by 36 minutes compared with
heparin (p<0.0001) (Schussler et al 2004). In this study, the
femoral sheath was removed when the ACT was below 200
seconds in bivalirudin-treated patients, and below 180
seconds in those receiving heparin. In this study, nearly 80%
of patients had an ACT lower than 200 at 2.5 hours. In
bivalirudin-treated patients, removal of the femoral sheath
at 2 hours appears to be a safe strategy.
UFH and to a much lesser extent LMWHs can be
inactivated by platelet factor (PF)-4, a substance released
from activated platelets (Eitzman et al 1994). DTIs do not
experience platelet factor PF4 inhibition. The UFH/PF4 or
LMWH/PF4 complex is also the initiator of immunoglobulin
Figure 1 The activity of DTIs is produced by direct interaction with the
thrombin molecule. The bivalent DTIs simultaneously bind the exosite 1 and the
active (catalytic) site. The univalent DTIs interact only with the active site.
Abbreviations: DTI, direct thrombin inhibitor.
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G mediated heparin induced thrombocytopenia (type II HIT)
(Chong 2003). There is no risk of type II heparin induced
thrombocytopenia with the DTIs. Bivalirudin has been
evaluated as an anticoagulant for PCI in patients with a
history of HIT (Mahaffey et al 2003). Among the 52 patient
studied, there were no episodes of thrombocytopenia
(platelet count <50 x 109/L), suggesting bivalirudin may be
an acceptable alternative to the heparins in this group.
Bivalirudin in ACS and PCI – the
early trials
Early trials of bivalirudin as an anticoagulant in acute
coronary syndromes (ACS) and PCI suggested similar
ischemic end points as the heparins, with lower rates of
bleeding. The Bivalirudin Angioplasty Trial (BAT) evaluated
4312 patients, randomized to either bivalirudin or heparin,
who underwent balloon angioplasty for unstable or post-
infarction angina (Bittl et al 1995). In the overall cohort,
there was no difference in the primary composite end point
of in-hospital death, MI, requirement for intra-aortic balloon
pump, or emergency revascularization. In the group
undergoing angioplasty following MI, bivalirudin was
associated with a lower incidence of the primary end point
(9.1% vs 14.2%, p=0.04). There was no difference in the
primary end point in patients undergoing angioplasty for
unstable angina without MI. Bivalirudin was associated with
lower rates of bleeding complications than heparin. These
were, retroperitoneal hemorrhage (0.2% vs 0.7%, p=0.02),
need for transfusion (3.7% vs 8.6%, p<0.001), and major
hemorrhage (3.8% vs 9.8%, p<0.001) respectively.
The Comparison of Abciximab with Hirulog for
Ischemic Events Trial (CACHET) was the first to examine
the safety and efficacy of bivalirudin in the modern PCI
environment of stenting and GP IIb/IIIa inhibitors (Lincoff
et al 2002). The trial randomized 268 patients to different
doses of bivalirudin with planned or provisional abciximab
use. The control group was low dose weight-adjusted
heparin with abciximab. There was no additional risk of
bleeding noted in the bivalirudin groups. When the three
bivalirudin groups were pooled, there was a lower incidence
of the composite end point of death, MI, revascularization
or major bleeding with bivalirudin, 3.4% vs heparin and
abciximab 10.6% (p=0.18). While this was a small pilot
study, it demonstrated two important points. Firstly that
bivalirudin appeared safe to use with GP IIb/IIIa inhibitors.
Secondly, bivalirudin was used with only provisional GPIIb/
IIIa inhibitor (24% in this trial), without a loss of efficacy.
The Randomized Evaluation in PCI Linking Angiomax
to Reduced Clinical Events (REPLACE)-1 trial was a pilot
study of 1056 patients undergoing elective or urgent PCI
(Lincoff et al 2002). Patients were randomized to heparin
or bivalirudin. All patients received aspirin and pretreatment
with clopidogrel was encouraged. The use of glycoprotein
IIb/IIIa inhibitors was at the physician’s discretion. The
combined end point of death, MI, or repeat revascularization
was reduced by 19% in the bivalirudin-treated patients at
48 hours (p=NS). The larger REPLACE-2 trial involved
6010 patients (Lincoff et al 2003). This trial was designed
to test the non-inferiority of bivalirudin with provisional
GP IIb/IIIa inhibitor compared with heparin and GP IIb/
IIIa inhibitor. The cohort studied was undergoing elective
PCI or PCI for non-ST elevation ACS. Patients undergoing
PCI for ST segment elevation myocardial infarction were
not included. Approximately 50% of patients underwent PCI
for an acute coronary syndrome. Multi-vessel intervention
was undertaken in around 15% of patients, and saphenous
vein graft intervention was undertaken in 6% of cases.
Patients randomized to the heparin arm were planned to
receive a GP IIb/IIIa antagonist (either abciximab or
eptifibatide). In those randomized to bivalirudin, GP IIb/
IIIa antagonists were permitted for procedural
complications. These included coronary dissection,
thrombus formation, unplanned stenting, slow flow, distal
embolization and ongoing instability. Provisional GP IIb/
IIIa inhibitor was used in 7.2% of the bivalirudin group.
The primary end point was a composite of death, MI, urgent
repeat revascularization, or major in-hospital bleeding by
30 days. There was no significant difference in the primary
end point between heparin plus GP IIb/IIIa inhibitor and
the bivalirudin group (10.0% vs 9.2%; OR 0.92; 95% CI,
0.77–1.09, p=0.32). A small excess of peri-procedural non-
Q wave myocardial infarctions was noted in the bivalirudin
group (6.6% bivalirudin vs 5.8% heparin, p=0.43). This
difference was due to a small excess in CKMB elevation 5–
10 times the upper limit of normal. This did not reach
statistical significance and the clinical relevance is unclear.
There were no identified differences in efficacy noted in
the major subgroups of the trial. While there were no
significant differences in the ischemic end points between
the two groups, there was a significant difference in bleeding
complications. There was a 41% relative reduction in major
bleeding among patients treated with bivalirudin (2.4% vs
4.1%, p<0.001).
The REPLACE-2 trial has reported end-point data at 6
months and 1 year (Lincoff et al 2004b). At 6 months, thereVascular Health and Risk Management 2006:2(4) 360
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was no significant difference in the two groups in the rates
of death, myocardial infarction or need for revascularization.
At 1 year, there was a non-significant trend towards
improved survival in the bivalirudin group. This has
alleviated some of the concerns regarding the non-significant
trend of increased peri-procedural non-Q wave myocardial
infarction with bivalirudin.
A pooled analysis has been performed of the clinical
trials evaluating bivalirudin in PCI (Ebrahimi et al 2005).
This included 11 638 treated patients, 5,861 with bivalirudin
and 5,777 with heparin. Bivalirudin was associated with a
reduction in the incidence of death, MI, revascularization,
and major bleeding (7.8% vs 10.8%, p<0.001) at 48 hours.
A benefit in mortality was observed (0.01% vs 0.02%,
p=0.049), with a more substantial reduction in major
bleeding (2.7% vs 5.8%, p<0.001).
Bivalirudin appears safe to use with the usual antiplatelet
agents aspirin, clopidogrel, and GP IIb/IIIa inhibitors. There
were lower clinical events in the bivalirudin group of
REPLACE-2 who were pre-treated with clopidogrel (Saw
et al 2004). This did not achieve statistical significance in
the heparin/GP IIb/IIIa group.
The cohort of patients with renal impairment presenting
with acute coronary syndromes are at higher risk for
complications. Pooled analyses from BAT, CACHET and
REPLACE-1 and an analysis from REPLACE-2 have
demonstrated increased risk of bleeding and ischemic events
in patient with renal impairment treated with heparin and
with combination of a heparin with a GP IIb/IIIa inhibitor
(Chew et al 2003, 2005). The relative benefit of bivalirudin
with respect to ischemic and bleeding events appears to be
maintained at each stratum of renal function. The absolute
benefit in terms of ischemic and bleeding complications
increased with decreasing creatinine clearance, normal
(>90 mL/min) 2.2%, mild (90–60 mL/min) 5.8%, moderate
(59–30 mL/min) 7.7%, and severe (<30 mL/min) 14.4%, p
trend <0.001, interaction p=0.044.
Small studies have been conducted with bivalirudin in
the setting of drug eluting stents, brachytherapy and
peripheral intervention (Allie et al 2005; Dangas et al 2005;
Kuchulakanti et al 2005). Evidence from these studies
appears to indicate the safety and efficacy of bivalirudin in
these settings.
An economic analysis has been performed on the basis
of data from the REPLACE 2 trial (Cohen et al 2004). Costs
were analyzed on the basis of market cost of pharmaceuticals
and calculated costs of care at the Beth Israel Deaconess
Medical Centre. The economic analysis favored bivalirudin.
The absolute cost saving per patients for the period of
hospitalization was US$405. In this analysis, 80% of the
cost saving was due to a reduction in the cost of
pharmaceuticals (GP IIb/IIIa inhibitor). This is despite the
provisional use of GP IIb/IIIa inhibitor in around 7% of
patients in the REPLACE-2 trial.
Results of the Randomized Trial to Evaluate the Relative
Protection against Post-PCI Microvascular Dysfunction and
Post-PCI Ischaemia among Anti-Platelet and Anti-
Thrombotic Agents – Thrombolysis in Myocardial Infarction
30 (PROTECT-TIMI 30) trial have recently been published
(Gibson et al 2006). This study examined the coronary flow
reserve after PCI in the setting of non-ST segment elevation
ACS with eptifibatide and either UFH or enoxaparin or
bivalirudin monotherapy. The primary end point of coronary
flow reserve is a marker of coronary microvascular function.
Bivalirudin monotherapy was associated with higher
coronary flow reserves than an eptifibatide and heparin
strategy (1.43 vs 1.33, p=0.036). TIMI perfusion grade was
more often normal with eptifibatide treatment compared with
bivalirudin (57.9% vs 50.9%, p=0.048). The duration of
ischemia as measured by Holter monitoring was significantly
longer in the bivalirudin treated patients (169 vs 36 min,
p=0.013). Bivalirudin was associated with lower rates of
TIMI minor bleeding (0.4% vs 2.5%, p=0.027) and
transfusion (0.4% vs 4.4%, p<0.001) compared with
eptifibatide combined with a heparin.
The acuity trial
The Acute Catheterization and Urgent Intervention Triage
Strategy (ACUITY) trial enrolled 13 819 patients with
moderate to high risk ACS undergoing an invasive strategy
(Stone et al 2004; Stone 2006a, b). All patients were treated
with aspirin and clopidogrel was encouraged. The timing
and dose of clopidogrel was left to the treating physician.
Patients were first randomized to one of three groups (Figure
2). These were a group of heparins (either enoxaparin or
UFH) and GP IIb/IIIa inhibitor, bivalirudin and GP IIb/IIIa
inhibitor or bivalirudin alone. The bivalirudin only group
had the option of bail out GP IIb/IIIa for thrombotic
complications during PCI. The two groups using planned
GP IIb/IIIa inhibitors underwent a second randomization to
either initial (upstream) GP IIb/IIIa inhibitor therapy or
therapy during PCI. The GP IIb/IIIa used upstream were
predominantly eptifibatide and tirofiban. The GP IIb/IIIa
inhibitors used in the catheterization laboratory were
predominantly abciximab and eptifibatide. The dose ofVascular Health and Risk Management 2006:2(4) 361
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bivalirudin was 0.1 mg/kg I.V. bolus and then 0.25 mg/kg/
hour pre-angiography. In the catheterization laboratory, a
bolus of 0.5 mg/kg was given, then infusion at a rate of
1.75 mg/kg/hour. Bivalirudin was discontinued at the end
of the procedure. There was an option for continued therapy
for 4–12 hours if a GP IIb/IIIa inhibitor was not used.
Figure 2 Design of the ACUITY trial. Patients with moderate to high risk ACS were first randomized to one of three groups. For the groups including a GPI, a
second randomization occurred to either up-stream or deferred GPI. Angiography was undertaken within 72 hours, and patients were then treated medically,
surgically or with (PCI) on clinical grounds.
Abbreviations: ACS, acute coronary syndrome; CABG, coronary artery bypass graft; GPI, glycoprotein IIb/IIIa inhibitor; PCI, percutaneous coronary intervention.
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Figure 3 Thirty-day events for UFH/enoxaparin plus GP IIb/IIIa inhibitor versus bivalirudin monotherapy in the ACUITY trial. PNI is the non-inferiority p value. Psup
is the superiority p value.
Abbreviations: GPI, glycoprotein IIb/IIIa inhibitor; UFH, unfractionated heparin.
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There were three pre-specified primary end points. The
ischemic composite consisted of death, myocardial
infarction, and unplanned revascularization. There was a
major bleeding end point that included predominantly non
coronary bypass related bleeding events. The third was a
net clinical benefit, taking into account both the ischemic
and bleeding end points. When the heparins with GP IIb/
IIIa inhibitor group was compared with bivalirudin plus GP
IIb/IIIa inhibitor, the bivalirudin group was non-inferior with
regard to the composite ischemic, major bleeding, and net
clinical outcome end points. Preliminary data have been
reported in abstract form at the time of publication. The 30-
day events rates (heparins/GP IIb/IIIa inhibitor vs
bivalirudin/GP IIb/IIIa inhibitor) for net clinical outcome
were 11.7% vs 11.8%, ischemic composite 7.3% vs 7.7%,
and major bleeding 5.7% vs 5.3% respectively. When the
heparins and GP IIb/IIIa inhibitor group was compared with
bivalirudin-only therapy, bivalirudin was non-inferior in the
triple ischemic endpoint (7.3% vs 7.8%, p=0.32).
Bivalirudin was superior for major bleeding (5.7% vs 3.0%,
p<0.0001). The reduction in bleeding events resulted in
bivalirudin being superior in the net clinical end point, RR
0.86 (0.77–0.95) p<0.015. Hence, in this large multicenter
trial using modern management for ACS, bivalirudin
monotherapy markedly reduced rates of bleeding without
loss of efficacy in the ischemic end points (Figure 3).
The ACUITY trial also examined the timing of GP IIb/
IIIa inhibitor use in a second randomization in patients
assigned to the GP IIb/IIIa inhibitor groups (Stone 2006a,
b). Patients in these two groups were assigned to either
receive up-stream GP IIb/IIIa inhibitor or deferred for
administration in the catheterization laboratory for the
patients undergoing PCI. Previous trials have demonstrated
benefits of early (up-stream) GP IIb/IIIa inhibitor in this
setting. Early data in abstract form from the ACUITY trial
suggested no difference in the 30-day net clinical outcome
between upstream and deferred GP IIb/IIIa inhibitor (11.7%
vs 11.7%, p=0.93). The deferred GP IIb/IIIa strategy failed
to meet non-inferiority for the ischemic composite (7.1 vs
7.9%, p=0.06). There was a significantly higher rate of
unplanned revascularization for ischemia (2.1% vs 2.8%,
p=0.03). There was a significant reduction in 30-day major
bleeding events in patients randomized to the deferred GP
IIb/IIIa strategy (6.1% vs 4.9%, p=0.009).
Summary
Multiple clinical trials now demonstrate that bivalirudin is
a safe and effective anticoagulant for use in ACS and PCI.
The reduction in bleeding complications compared with
heparin-based strategies has been a consistent finding across
these studies. This has been demonstrated without loss of
efficacy in the prevention of thrombotic complications.
Depending on the cost of bivalirudin, there may be economic
benefit created through a reduction in the need for GP IIb/
IIIa inhibitors and reduced rates of bleeding in both ACS
and PCI.
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